| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 70,445 | 239,240 | 666,655 | 84,512 |
| Selling, general, and administrative | - | 43,612 | 48,090 | 70,747 |
| Cost of sales | 21,496 | 15,325 | 14,115 | 60,619 |
| Research and development | 98,274 | 79,233 | 88,937 | 87,164 |
| Selling, general, and administrative | 31,655 | - | - | - |
| Impairment of assets held for sale | 97,038 | - | - | - |
| Total expenses | 248,463 | 138,170 | 151,142 | 218,530 |
| Income (loss) from operations | -178,018 | 101,070 | 515,513 | -134,018 |
| Interest expense | 5,482 | 5,518 | 5,723 | 4,236 |
| Loss on debt extinguishment | -28,714 | - | - | - |
| Other income, net | 9,178 | 11,902 | 10,056 | 15,922 |
| Income (loss) before income tax expense | -203,036 | 107,454 | 519,846 | -122,332 |
| Income tax expense (benefit) | -657 | 946 | 1,200 | -1,032 |
| Net income (loss) | -202,379 | 106,508 | 518,646 | -121,300 |
| Basic (in shares) | 162,353,000 | 162,019,000 | 161,049,000 | 160,049,000 |
| Basic (in usd per share) | -1.25 | 0.66 | 3.22 | -0.76 |
| Diluted (in shares) | 162,353,000 | 177,215,000 | 177,625,000 | 160,049,000 |
| Diluted (in usd per share) | -1.25 | 0.62 | 2.93 | -0.76 |
NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX)